Episode #102: Hybrid Peptides, Peptide Research Updates, and Bioregulators
LONGEVITY with Nathalie Niddam
00:00
Is Bimasenalpaon in the Mainstream Medicine?
It would have to get broken down for it even make it to ok. Just parenthesis throws it back to theehe hybrid. The future is that paracinical companies will be able to patent those hybrids, because they're not ally made. But the other thing is, of course, they're going to sell them expensive ut you know, insurance and things. Actually, looking at it this way, bright future, i agree.
Play episode from 14:59
Transcript
